نمایش پرونده ساده آیتم

dc.contributor.authorRostamzadeh, D
dc.contributor.authorRazavi, SR
dc.contributor.authorEsmaeili, S
dc.contributor.authorDolati, S
dc.contributor.authorAhmahi, M
dc.contributor.authorSadreddini, S
dc.contributor.authorJadidi-Niaragh, F
dc.contributor.authorYousefi, M
dc.date.accessioned2018-08-26T05:36:30Z
dc.date.available2018-08-26T05:36:30Z
dc.date.issued2016
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/39548
dc.description.abstractSystemic lupus erythematous (SLE) is a chronic heterogeneous multisystem autoimmune disease characterized by loss of tolerance to self-antigens and production of numerous autoantibodies. Current therapeutic approaches used to treat inflammatory autoimmune diseases are associated with debilitating side effects. In spite of significant advances in therapeutic options and increased understanding of the pathogenesis, novel therapeutic approaches are needed for treatment of SLE. Nanoparticle-based delivery systems that selectively deliver drugs to inflamed tissue or specific cell have the potential to improve drug delivery. This article reviews recent nanotechnology-based therapeutics strategies that are being developed for the treatment of SLE.
dc.language.isoEnglish
dc.relation.ispartofBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
dc.subjectHumans
dc.subjectLupus Erythematosus, Systemic
dc.subjectModels, Biological
dc.subjectNanoparticles
dc.subjectNanotechnology
dc.titleApplication of nanoparticle technology in the treatment of Systemic lupus erythematous.
dc.typearticle
dc.citation.volume83
dc.citation.spage1154
dc.citation.epage1163
dc.citation.indexPubmed
dc.identifier.DOIhttps://doi.org/10.1016/j.biopha.2016.08.020


فایلهای درون آیتم

فایلهاسایزفرمتنمایش

هیچ فایل مرتبطی وجود ندارد

این آیتم در مجموعه های زیر مشاهده می شود

نمایش پرونده ساده آیتم